Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization

References

• Abrishami M, Ganavati SZ, Soroush D, et al. (2009). Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina 29:699–703.
   PubMed Web of Science ®Google Scholar
• And MSS, Zasadzinski JA, Sankaram MB. (1996). Topology of multivesicular liposomes, a model biliquid foam. Langmuir 12:4704–8.
   Web of Science ®Google Scholar
• Angkawinitwong U, Awwad S, Khaw PT, et al. (2017). Electrospun formulations of bevacizumab for sustained release in the eye. Acta Biomater 64:126–36.
   PubMed Web of Science ®Google Scholar
• Ardeljan D, Chan CC. (2013). Aging is not a disease: distinguishing age-related macular degeneration from aging. Prog Retinal Eye Rese 37:68–89.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. (2007). Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855–9.
   PubMed Web of Science ®Google Scholar
• Bilati U, Allémann E, Doelker E. (2005). Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm 59:375–88.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Soloway P, Ryan SJ, et al. (1999). The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis 5:34
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G, et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435–9.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liu D, Wang J, et al. (2014). Development of nanoparticles-in-microparticles system for improved local retention after intra-articular injection. Drug Deliv 21:342–50.
   PubMed Web of Science ®Google Scholar
• Cleland JL, Jones AJS. (1996). Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable mircospheres. Pharm Res 13:1464–75.
   PubMed Web of Science ®Google Scholar
• Ellena JF, Le M, Cafiso DS, et al. (1999). Distribution of phospholipids and triglycerides in multivesicular lipid particles. Drug Deliv 6:97–106.
   Web of Science ®Google Scholar
• Haghjou N, Soheilian M, Abdekhodaie MJ. (2011). Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res 6:317–29.
   PubMedGoogle Scholar
• Hasan AS, Sapin A, Damgé C, et al. (2015). Reduction of the invivo burst release of insulin-loaded microparticles. J Drug Deliv Sci Technol 30:486–93.
   Web of Science ®Google Scholar
• Holzschuh S, Kaesz K, Bossa GV, et al. (2018). Investigations of the influence of liposome composition on vesicle stability and drug transfer in human plasma: a transfer study. J Lipos Res 28:22–34.
   PubMed Web of Science ®Google Scholar
• Jain SK, Jain RK, Chourasia MK, et al. (2005). Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium. AAPS PharmSciTech 6:E35–41.
   PubMed Web of Science ®Google Scholar
• Jiskoot W, Randolph TW, Volkin DB, et al. (2012). Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci 101:946–54.
   PubMed Web of Science ®Google Scholar
• Kamizuru H, Kimura H, Yasukawa T, et al. (2001). Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci 42:2664–72.
   PubMed Web of Science ®Google Scholar
• Kang F, Jiang G, Hinderliter A, et al. (2002). Lysozyme stability in primary emulsion for PLGA microsphere preparation: effect of recovery methods and stabilizing excipients. Pharm Res 19:629–33.
   PubMed Web of Science ®Google Scholar
• Katre NV, Asherman J, Schaefer H, et al. (1998). Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-I (IGF-I). J Pharm Sci 87:1341–6.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kakkar S. (2014). Nanotherapy for posterior eye diseases. J Control Release 193:100–12.
   PubMed Web of Science ®Google Scholar
• Kim S, Turker MS, Chi EY, et al. (1983). Preparation of multivesicular liposomes. Biochim Biophys Acta 728:339–48.
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Souied EH, Mimoun G, et al. (2013). Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 120:2300–9.
   PubMed Web of Science ®Google Scholar
• Kohn FR, Malkmus SA, Brownson EA, et al. (1998). Fate of the predominant phospholipid component of DepoFoam drug delivery matrix after intrathecal administration of sustained-release encapsulated cytarabine in rats. Drug Deliv 5:143–51.
   PubMed Web of Science ®Google Scholar
• Langston MV, Ramprasad MP, Kararli TT, et al. (2003). Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). J Control Release 89:87–99.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Koo H, Jeong H, et al. (2011). Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy. J Control Release 152:21–9.
   PubMed Web of Science ®Google Scholar
• Lee TH, Wang J, Wang CH. (2002). Double-walled microspheres for the sustained release of a highly water soluble drug: characterization and irradiation studies. J Control Release 83:437–52.
   PubMed Web of Science ®Google Scholar
• Li F, Hurley B, Yun L, et al. (2012). Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 6:54–8.
   PubMedGoogle Scholar
• Li X, Zhang Z, Chen H. (2013). Development and evaluation of fast forming nano-composite hydrogel for ocular delivery of diclofenac. Int J Pharm 448:96–100.
   PubMed Web of Science ®Google Scholar
• Mantripragada S. (2002). A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res 41:392–406.
   PubMed Web of Science ®Google Scholar
• Meinel L, Illi OE, Zapf J, et al. (2001). Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. J Control Release 70:193–202.
   PubMed Web of Science ®Google Scholar
• Meisner D, Mezei M. (1995). Liposome ocular delivery systems. Adv Drug Deliv Rev 16:75–93.
   Web of Science ®Google Scholar
• Meyer J, Whitcomb L, Collins D. (1994). Efficient encapsulation of proteins within liposomes for slow release in vivo. Biochem Biophys Res Commun 199:433–8.
   PubMed Web of Science ®Google Scholar
• Mi VDR, La Heij EC, De JY, et al. (2011). A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31:1449–69.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Thomsen K, Licko V, et al. (1999). Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 52:101–6.
   PubMed Web of Science ®Google Scholar
• Neves Cardoso P, Pinheiro AF, Meira J, et al. (2017). Switch to aflibercept in the treatment of neovascular AMD: long-term results. J Ophthalmol 2017:6835782.
   PubMed Web of Science ®Google Scholar
• Nomoto H, Shiraga F, Kuno N, et al. (2009). Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 50:4807–13.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Smith DJ. (2004). Preferential hydration and the exclusion of cosolvents from protein surfaces. J Chem Phys 121:1148–54.
   PubMed Web of Science ®Google Scholar
• Son S, Lee WR, Joung YK, et al. (2009). Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int J Pharm 368:178–85.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF, et al. (2006). Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–90.
   PubMed Web of Science ®Google Scholar
• Vannewkirk MR, Nanjan MB, Wang JJ, et al. (2000). The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 107:1593–600.
   PubMed Web of Science ®Google Scholar
• Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, et al. (2013). The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci 50:341–52.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fei D, Vanderlaan M, et al. (2004). Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335–45.
   PubMedGoogle Scholar
• Xu X, Weng Y, Xu L, et al. (2013). Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery. Int J Biol Macromol 60:272–6.
   PubMed Web of Science ®Google Scholar
• Ye Q, Asherman J, Stevenson M, et al. (2000). DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J Control Release 64:155–66.
   PubMed Web of Science ®Google Scholar
• Zampros I, Praidou A, Brazitikos P, et al. (2012). Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol 2012:319728
   PubMed Web of Science ®Google Scholar
• Zhang L, Ding L, Tang C, et al. (2016). Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes. Drug Deliv 23:3358–63.
   PubMed Web of Science ®Google Scholar